Latest Commercial Sales News

Memphasys Limited has marked a milestone quarter with revenue surpassing A$100,000, driven by repeat orders and multi-year contracts, signalling its transition to a commercially focused biotech business.

Aguia Resources’ Brazilian subsidiary has achieved a key regulatory milestone with official fertiliser registration, enabling commercial sales of its PAMPAFOS phosphate product in Brazil’s large agricultural market.

Syrah Resources has opened its retail entitlement offer to raise approximately A$104 million, supported by strategic funding proposals from US and Australian government-linked entities. The capital raise aims to underpin the ramp-up of its Balama graphite mine and Vidalia anode material facility.

GCM Corporation has launched its first Very High Density (VHD) heat sink product line, marking a pivotal step from development to commercial sales in thermal management technology.

Firebrick Pharma has secured its first regulatory approval for Nasodine Nasal Spray in Indonesia, paving the way for entry into Southeast Asia’s largest market. This milestone marks a significant step in the company’s international expansion strategy.

Green360 Technologies has inked a binding toll treatment agreement with Calix Limited to commercially produce Eco-Clay, a low-carbon cement replacement, marking a key step toward scaling sustainable concrete solutions in Australia.

Rhythm Biosciences has completed the first commercial sale of its ColoSTAT® blood test for colorectal cancer, confirming the full clinical and logistical process is operational and ready for expansion.

Avecho Biotechnology has completed recruitment for the interim analysis cohort of its pivotal Phase III trial for a CBD insomnia treatment, with results expected in June 2026. This milestone could significantly de-risk the program and unlock major market opportunities.

Mesoblast Limited reported its first commercial sales of FDA-approved Ryoncil, generating $48.7 million in net product sales for the half-year ended December 31, 2025, while reducing its net loss by 16%. The company also secured a $125 million five-year credit facility, restructuring its debt to support ongoing commercialization and development.

Neuren Pharmaceuticals reports a 15% rise in 2025 royalties from its partner Acadia’s DAYBUE sales, with strong 2026 guidance signalling further growth. The launch of a new powder formulation and ongoing regulatory efforts in Europe and Japan add to the momentum.

XReality Group has reported its strongest half-year performance yet, driven by rapid growth in its Operator XR business focused on immersive training solutions for defence and law enforcement.

xReality Group Limited has reported a robust half-year performance with revenue climbing 41% to $10.4 million, driven by rapid expansion of its Operator XR platform. EBITDA surged 190%, underscoring the company’s successful pivot to software-led immersive training solutions.